Abstract 539P
Background
Despite hepatectomy being the cornerstone for colorectal liver metastasis (CRLM) management, the postoperative 1-year recurrence rate remains alarmingly high (∼70%). This Phase II trial assesses the efficacy and safety of an adjuvant combination therapy of hepatic arterial infusion chemotherapy (HAIC) with Sintilimab and Regorafenib in pts with high-risk CRLM.
Methods
Post-hepatectomy pts with histologically confirmed CRLM and a Clinical Risk Score (CRS) ≥2 were included in this study. HAIC -FOLFOX was administered every 4-6 weeks (2-4 cycles based on patient health status), alongside Sintilimab (200mg, iv, day1) and Regorafenib (80mg, po, days 1-21) every 3 weeks for up to 2 years. The primary endpoint was the 1-year recurrence-free survival (1y-RFS), with secondary endpoints including TTP, OS, RFS, and safety.
Results
From August 2022 to April 2024, 35 pts with a median age of 56 (range 38-71) were enrolled. 60% were male, 40% had K-RAS mutations, all presented with an ECOG 0 and Child-Pugh class A. Majority (74.3%) had the primary tumor in the left colon, and 45.7% presented with synchronous liver metastases. Prior to hepatectomy, 80% had ≥2 liver metastases, and 22.9% had the largest liver tumor diameter >5 cm. CRS scores were 2 (42.9%), 3 (34.3%), 4 (20%), and 5 (2.9%). At a median follow-up of 13.1 months (range 11.3-20.8), 32 pts underwent at least one efficacy evaluation, 9 experienced recurrence or death within 1 year. 1y-RFS exceed the hypothesis, achieving 67.8%. TTP, OS and RFS have not yet been reached. Adverse events (AEs) occurred in 60% of pts, consistent with TRAEs. Common TRAEs included hand-foot syndrome (20%), rash (17.1%), and emesis (17.1%). Grade ≥3 TRAEs were limited to rash (2.9%) and decreased platelet count (2.9%). Drug suspensions occurred in 11.4%, with 17.1% discontinuing Regorafenib due to TRAEs.
Conclusions
The adjuvant combination of HAIC, Sintilimab, and Regorafenib demonstrates feasible efficacy and an acceptable safety profile for high-risk CRLM. Further detailed analysis is warranted to confirm long-term benefits and safety of this regimen.
Clinical trial identification
NCT05753163.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors
Presenter: Timothy Anthony Yap
Session: Poster session 15
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15